State of Wisconsin Investment Board acquired a new stake in Insys Therapeutics, Inc. (NASDAQ:INSY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 19,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $240,000.

Other hedge funds have also made changes to their positions in the company. Bank of Montreal Can increased its position in shares of Insys Therapeutics by 215.3% during the 1st quarter. Bank of Montreal Can now owns 20,812 shares of the specialty pharmaceutical company’s stock worth $219,000 after purchasing an additional 14,212 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Insys Therapeutics during the 1st quarter worth about $188,000. Wells Fargo & Company MN increased its position in shares of Insys Therapeutics by 30.3% during the 1st quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock worth $289,000 after purchasing an additional 6,407 shares in the last quarter. First Trust Advisors LP increased its position in shares of Insys Therapeutics by 105.3% during the 1st quarter. First Trust Advisors LP now owns 147,788 shares of the specialty pharmaceutical company’s stock worth $1,553,000 after purchasing an additional 75,817 shares in the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new stake in shares of Insys Therapeutics during the 1st quarter worth about $172,000. Institutional investors own 25.45% of the company’s stock.

In other Insys Therapeutics news, major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the stock in a transaction on Friday, August 11th. The stock was purchased at an average price of $8.93 per share, with a total value of $156,275.00. Following the completion of the purchase, the insider now owns 31,982 shares in the company, valued at $285,599.26. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Saeed Motahari bought 5,500 shares of the stock in a transaction on Thursday, August 10th. The shares were acquired at an average cost of $8.92 per share, with a total value of $49,060.00. Following the purchase, the chief executive officer now owns 15,400 shares of the company’s stock, valued at approximately $137,368. The disclosure for this purchase can be found here. 67.90% of the stock is owned by insiders.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/16/state-of-wisconsin-investment-board-takes-240000-position-in-insys-therapeutics-inc-insy.html.

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada set a $16.00 target price on shares of Insys Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 target price for the company in a research report on Wednesday, July 12th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Insys Therapeutics presently has an average rating of “Hold” and an average target price of $13.25.

Shares of Insys Therapeutics, Inc. (INSY) opened at 9.22 on Friday. The firm’s market cap is $670.26 million. Insys Therapeutics, Inc. has a 12 month low of $8.70 and a 12 month high of $15.06. The company’s 50 day moving average is $9.58 and its 200-day moving average is $11.21.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million during the quarter, compared to the consensus estimate of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. Insys Therapeutics’s revenue for the quarter was down 38.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 earnings per share. Equities research analysts predict that Insys Therapeutics, Inc. will post ($0.29) EPS for the current year.

Insys Therapeutics Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.